To the full analysis
Alibaba Health Information Technology stock: growth
0241.HKAlibaba Health Information Technology reported $5.14B in revenue for fiscal 2026, up 12% on the prior year, up 17.2% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
28.7%
per year from 2007 to 2026, per share 18.4%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2021 | since 2016 | since 2007 | |
|---|---|---|---|
| Revenue | 17.2% | 89.8% | 28.7% |
| Revenue per share | 12.5% | 77.2% | 18.4% |
| Earnings | 40.9% | no data | no data |
| Earnings per share | 35.5% | no data | no data |
| Free cash flow | 4.3% | no data | no data |
| Free cash flow per share | 0.2% | no data | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2007 | $42.4M | −$9.57M | −$21.76M |
| 2008 | $31.54M | −$10.98M | −$6.31M |
| 2009 | $36.32M | −$19.57M | −$430.97K |
| 2010 | $37.97M | −$6.8M | −$5.3M |
| 2011 | $47.09M | −$3.33M | −$4.99M |
| 2012 | $58.68M | −$942.37K | −$1.37M |
| 2013 | $1.91M | −$4.97M | −$1.25M |
| 2014 | $3.3M | −$4.7M | −$373.96K |
| 2015 | $4.46M | −$12.18M | −$8.83M |
| 2016 | $8.49M | −$28.73M | −$18.88M |
| 2017 | $71.24M | −$31.14M | −$34.25M |
| 2018 | $366.31M | −$16.04M | −$11.4M |
| 2019 | $764.2M | −$12.29M | $58.53M |
| 2020 | $1.44B | −$987.66K | $86.39M |
| 2021 | $2.33B | $52.28M | $148.82M |
| 2022 | $3.09B | −$39.82M | $61.4M |
| 2023 | $4.01B | $80.33M | $37.5M |
| 2024 | $4.05B | $132.49M | $158.52M |
| 2025 | $4.59B | $214.81M | $206.37M |
| 2026 | $5.14B | $290.35M | $184.1M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2026, period end 31 Mar 2026
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = HK$7.8782, $1 = CN¥6.6683)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 17 Jan 2025)
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.